Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupTumor, regardless of entityUrologic OncologyDiseaseRenal Cell CarcinomaTumor, Various OrgansSubgroupICD10C64MeSHCarcinoma, Renal CellKidney NeoplasmsNeoplasmsSequenceChemotherapyChemo-substanceLenvatinibPembrolizumabChemo-substanceLenvatinibPembrolizumabChemo-substanceLenvatinibPembrolizumabChemo-substanceLenvatinibPembrolizumabNo. Substances2 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionSupportive substanceBalanced Crystalloid SolutionSupportive substanceBalanced Crystalloid SolutionSupportive substanceBalanced Crystalloid SolutionNo. Substances1Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksAdrenal InsufficiencyArthalgiaColitisDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)HypertensionHypomagnesemiaHyponatremiaHypothyroidismPancreatitisPneumonitisProteinuriaRenal FailureThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorTaylor MHDiseaselokal fortgeschrittener oder metastasierter Tumor, unabhängig von der Entität, progredient nach 2 oder weniger Therapielinien, ECOG 0-1OriginKnight Cancer Institute, Oregon Health and Science University, Portland, USAProtocols in Revision 1 protocol foundProtocols under revision.Lenvatinib 20 / Pembrolizumab 200, Tumor, Various Organs (PID1518 V1.0)
